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Abstract
Background:  The nucleotide-binding oligomerization domain containing 1 (NOD1) gene encodes a
pattern recognition receptor that senses pathogens, leading to downstream responses characteristic of
innate immunity. We investigated the role of NOD1 single nucleotide polymorphisms (SNPs) on IBD risk
in a New Zealand Caucasian population, and studied Nod1 expression in response to bacterial invasion in
the Caco2 cell line.
Findings: DNA samples from 388 Crohn's disease (CD), 405 ulcerative colitis (UC), 27 indeterminate
colitis patients and 201 randomly selected controls, from Canterbury, New Zealand were screened for 3
common SNPs in NOD1, using the MassARRAY® iPLEX Gold assay. Transcriptional activation of the
protein produced by NOD1 (Nod1) was studied after infection of Caco2 cells with Escherichia coli LF82.
Carrying the rs2075818 G allele decreased the risk of CD (OR = 0.66, 95% CI = 0.50–0.88, p < 0.002) but
not UC. There was an increased frequency of the three SNP (rs2075818, rs2075822, rs2907748)
haplotype, CTG (p = 0.004) and a decreased frequency of the GTG haplotype (p = 0.02).in CD. The
rs2075822 CT or TT genotypes were at an increased frequency (genotype p value = 0.02), while the
rs2907748 AA or AG genotypes showed decreased frequencies in UC (p = 0.04), but not in CD.
Functional assays showed that Nod1 is produced 6 hours after bacterial invasion of the Caco2 cell line.
Conclusion: The NOD1 gene is important in signalling invasion of colonic cells by pathogenic bacteria,
indicative of its' key role in innate immunity. Carrying specific SNPs in this gene significantly modifies the
risk of CD and/or UC in a New Zealand Caucasian population.
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Background
Pathogens are sensed by pattern recognition receptors
(PRRs), including cytosolic nucleotide oligomerisation
domain (Nod) proteins, resulting in downstream
responses involving the activation of transcription factors
and the induction of apoptosis genes. Intestinal epithelial
cells are among several cell types that express such pro-
teins, including Nod1 and Nod 2 [1].
Since initial publications claiming that single nucleotide
polymorphisms (SNPs) in NOD2 provide a major risk fac-
tor for CD [2,3], there have been many reports of other
susceptibility alleles [4]. Nod2 recognizes a range of bac-
teria through a cell wall peptidoglycan. However, the
related Nod1 may be even more important, since it senses
a wider range of pathogens. In epithelial cells, Nod1
appears to be indispensable for sensing of intracellular
gram-negative bacteria [1].
The NOD1 gene (MIM# 605980) is located on chromo-
some 7p14.3. An initial study reported no relationship
between SNPs in NOD1  and risk of IBD in European
patients [5]. However, McGovern and co-workers [6]
pointed out that the SNP tested was a rare variant, and
that the risk of complex diseases is associated with regula-
tory mutations that occur commonly in a population.
These authors reported an association between a complex
insertion/deletion polymorphism in NOD1 and suscepti-
bility to CD in a European population. However,
although Canto et al, [7] found similar results in their
Spanish subjects, several other studies have failed to repli-
cate this finding in other European populations [8-10].
Although the main focus of the original McGovern et al.,
[6] paper was on the complex deletion, associations were
also observed between IBD and several other SNPs,
including NOD1 c.156C>G (P < 0.02) and g27606C>T, (P
< 0.05). They also reported an association with haplo-
types containing g.45343G>A.
SNPs in the genes for three different pattern recognition
receptors (NOD2, DLG5 and TLR4) have been previously
associated with CD in the New Zealand population [11-
13]. Here we consider the implications of three different
NOD1 SNPs for their effects on IBD susceptibility in a
Caucasian population from the Canterbury region of New
Zealand. We also consider the functional role of Nod1 in
relation to invasion of the gastrointestinal colon cell line,
Caco2 by the CD-associated bacterium, Escherichia coli
LF82 [14].
Results
Case control study
Clinical and demographic characteristics of the IBD
cohort are given in Table 1. The SNPs selected for analysis
were: c.156C>G (rs2075818; synonymous SNP),
g.27606T>C (rs2075822; intronic SNP), and g.45343G>A
(rs2907748; intronic SNP) (Table 2; [6]).
Carrying the NOD1 c.156C>G variant led to statistically
significant changes in CD or overall IBD risk, but not UC
risk. Table 3 shows a significant difference in the major
(C) allele frequencies between CD patients (81.1%) and
controls (73.9%) (p = 0.004), such that those individuals
carrying the C allele have an increased probability of
developing CD in this population (OR = 1.51, 95% CI =
1.13–2.02, p = 0.004). CG heterozygotes have a reduced
risk of CD (OR = 0.53, 95% CI = 0.37–0.75, p = 0.002),
and of developing IBD as compared with CC homozy-
gotes (OR = 0.64, 95% CI = 0.46–0.88, p = 0.01).
Carrying the NOD1 g.27606C>T variant led to statistically
significant changes in the probability of developing UC,
but not CD (Table 3). The CT heterozygote had a 2.65-
fold (OR = 2.65, 95% CI = 1.29–5.41) greater risk, while
TT homozygotes had a 2.45-fold (OR = 2.45, 95% CI =
1.23–4.85) greater risk of developing the disease, as com-
pared with the risk for CC homozygotes (p = 0.02). For
g.45343G>A SNP, it is the major allele that carries the
increased risk. AG heterozygotes (OR = 2.32, 95% CI =
1.18–4.53) and GG homozygotes (OR = 2.19, 95% CI =
1.14–4.22) have an increased risk of developing the dis-
ease, as compared with AA homozygotes (p = 0.04). There
was no significant difference in the allele frequencies
between control subjects and CD, UC, or IBD patients
(Table 3).
We also report results from extensive subgroup analysis
using sets of cases defined by gender, age of diagnosis, dis-
ease location, disease behaviour, need for surgery, smok-
ing history, use of immunomodulators, and presence of
Table 1: NOD1 polymorphisms tested in the Canterbury population
rs Number Location Nucleotide changea Protein domain Frequencyb
rs2075818 Exon 4 c.156C>G CARD 0.869 (n = 214)
g.21984C>G
rs2075822 Intron 6 g.27606T>C 0.706 (n = 92)
rs2907748 Intron 11 g.45343G>A 0.735 (n = 200)
a. The position is numbered from the first nucleotide of exon 1. The sequence is obtained from dbSNP http://www.ncbi.nlm.nih.gov/SNP/.
b. Frequency of major SNPs in a European population as a mean for European samples submitted to dbSNP http://www.ncbi.nlm.nih.gov/SNP/.BMC Research Notes 2009, 2:52 http://www.biomedcentral.com/1756-0500/2/52
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family history of IBD (Table 4). While several of these cat-
egories showed substantially increased risks associated
with different SNPs, none explained an undue proportion
of the CD cases.
Table 5 summarises haplotype analysis. A positive hap-
score implies that the haplotype occurs more frequently in
the CD or UC case group. A global p-value tests the overall
association between haplotypes and the response.
These haplotypes differed significantly between CD
patients and control subjects (χ2 = 9.55, df = 3, p = 0.02)
(Table 5). Haplotype CTG frequencies in cases was 55.8%
and in controls 46.9% (p = 0.004). The frequencies of
haplotype GTG were 16.0% and 21.7% for CD case and
control subjects respectively (p = 0.02). Haplotypes CCG,
CTA, GCA, and GCG were the most uncommon in CD
cases and control subjects, and occurred at equal frequen-
cies in the two groups (p > 0.05). There were no significant
associations between these haplotypes for UC cases as
compared with control subjects (χ2 = 2.30, df = 3, p =
0.51). Haplotype CTG was the most common in UC cases
but occurred at equal frequencies between UC case and
control subjects (p > 0.05).
Crohn's disease-associated Escherichia coli LF82 leads to 
the transcriptional activation of Nod1
The gastrointestinal colon cell line Caco2 was infected
with LF82 for 6 h and 9 h, respectively. Infection with this
bacterial strain leads to increased Nod1 m RNA levels for
the 6 h time point (4.3 fold increase as measured using
quantitative real time PCR), whereas after 9 h infection
the Nod1 expression levels were similar to the uninfected
state (Figure 1). As Nod1 signalling leads to the activation
of NF-κB, we also tested the mRNA expression for this
gene. Infection of Caco2 cells with the E. coli strain LF82
results in an upregulation for NF-κB for 6 h (3.2 fold
increase) and 9 h (2.4 fold increase).
Discussion
The present study adds to a growing database supporting
a role for pattern recognition receptors ininflammatory
Table 2: Summary of clinical and demographic data for the set of Caucasian IBD patients
CD
n (%)
UC
n (%)
IC
n (%)
Gender
Female 249 (64.2) 214 (52.8) 15 (55.6)
Male 139 (35.8) 191 (47.2) 12 (44.4)
Age at first diagnosis
Below 17 39 (10.0) 26 (6.4) 0
Between 17 and 40 199 (51.3) 184 (45.4) 15 (55.6)
Above 40 150 (38.7) 195 (48.2) 12 (44.4)
CD location
Ileal 125 (32.2)
Colonic 169 (43.6)
Ileocolonic 90 (23.2)
Upper GI 4 (1.0)
UC location
Proctitis 140 (34.6) 3 (11.1)
Left colon 107 (26.4) 5 (18.5)
Pancolitis 154 (38.0) 19 (70.4)
Unknown 4 (1.0) 0
Behaviour
Non-stricturing, non-penetrating perianal disease 47 (21.5)
Stricturing perianal disease 46 (38.0)
Penetrating perianal disease 17 (35.4)
Any relative with IBD: Yes (n = 143) 74 (19.1) 65 (16.1) 5 (18.5)
Bowel resection: Yes (n = 214) 142 (36.6) 70 (17.3) 2 (7.4)
Smoker at diagnosis: Yes (n = 147) 97 (25.7) 49 (12.3) 2 (7.7)
Ever used immunomodulators: Yes (n = 296) 203 (52.3) 86 (21.2) 8 (29.6)
Extraintestinal manifestations: Yes (n = 142) 75 (19.3) 64 (15.8) 3 (11.1)BMC Research Notes 2009, 2:52 http://www.biomedcentral.com/1756-0500/2/52
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Table 3: Genotype and allele counts for NOD1/CARD4 variants in New Zealand IBD patients and in New Zealand Caucasians
SNP Controls CD UC CD+UC
n (%) n (%) OR
(95% CI)
n (%) OR
(95% CI)
n (%) OR
(95% CI)
NOD1 rs2075818
CC 105 (52.2) 255 (66.7) 1.29
(0.56–2.98)
226 (56.5) 0.61
(0.28–1.31)
481 (61.4) 0.84
(0.40–1.77)
CG 87 (43.3) 111 (29.0) 0.68
(0.29–1.59)
142 (35.5) 0.46
(0.21–1.01)
253 (32.3) 0.53
(0.25–1.13)
GG 9
(4.5)
17 (4.4) 1.00 32 (8.0) 1.00 49 (6.3) 1.00
Genotype p-value 0.002 0.08 0.01
HWE p-value 0.10 0.28 0.15 0.05
G 105 (26.1) 145 (18.9) 206 (25.8) 351 (22.4)
C 297 (73.9) 621 (81.1) 594 (74.3) 1215 (77.6)
OR (95% CI) 0.66 (0.49–0.89) 0.98 (0.74–1.30) 0.82 (0.63–1.06)
Allelic p-value 0.004 0.89 0.12
NOD1 rs2075822
CC 20 (10.0) 28
(7.3)
1.00 17
(4.2)
1.00 45
(5.7)
1.00
CT 60 (30.0) 122 (31.9) 1.45
(0.76–2.79)
135 (33.6) 2.65
(1.29–5.41)
257 (32.8) 1.90
(1.05–3.46)
TT 120 (60.0) 232 (60.7) 1.38
(0.75–2.55)
250 (62.2) 2.45
(1.23–4.85)
482 (61.5) 1.79
(1.02–3.14)
Genotype p-value 0.52 0.02 0.09
HWE p-value 0.007 0.04 0.82 0.17
C 100 (25.0) 178 (23.3) 169 (21.0) 347 (22.1)
T 300 (75.0) 586 (76.7) 635 (79.0) 1221 (77.9)
OR (95% CI) 0.91 (0.69–1.21) 0.80 (0.60–1.06) 0.85 (0.66–1.10)
Allelic p-value 0.52 0.12 0.22
NOD1 rs2907748
AA 21 (10.3) 31
(8.2)
1.00 20
(5.0)
1.00 51
(6.6)
1.00
AG 73 (36.7) 129 (34.3) 1.20
(0.64–2.23)
161 (40.3) 2.32
(1.18–4.53)
290 (37.4) 1.64
(0.93–2.89)
GG 105 (52.8) 216 (57.4) 1.39
(0.76–2.54)
219 (54.7) 2.19
(1.14–4.22)
435 (56.1) 1.71
(0.98–2.96)
Genotype p-value 0.48 0.04 0.16
HWE p-value 0.12 0.07 0.16 0.78
A 115 (28.9) 191 (25.4) 201 (25.1) 392 (25.3)
G 283 (71.1) 561 (74.6) 599 (74.9) 1160 (74.7)
OR (95% CI) 0.84 (0.64–1.10) 0.83 (0.63–1.08) 0.83 (0.65–1.06)
Allelic p-value 0.20 0.16 0.14BMC Research Notes 2009, 2:52 http://www.biomedcentral.com/1756-0500/2/52
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bowel diseases [4]. Previous data associating NOD1 poly-
morphisms with IBD risk showed variable results. Zouali,
et al., [5], with European subjects, and Ozen et al., [15]
with Turkish patients, concluded that NOD1  was not
involved in IBD. However, subject numbers in both stud-
ies were small. Molnar et al., [16] reported that the E266K
(c.796G>A)  NOD1 polymorphism was associated with
disease susceptibility but not with disease phenotype or
NOD2 or TLR4  polymorphisms in Hungarian patients
with CD.
Following the very strongly positive associations reported
by McGovern et al., [6], most of the more recent publica-
tions have focussed on the complex (ND(1)+32656*)
NOD1 deletion mutation. Canto et al, [7] reported that
the distribution of the NOD1 polymorphism in patients
was different from controls, and not altered by the exist-
ence of NOD2 mutations in their Spanish population.
However, Van Limbergen et al, [10,17] showed no statis-
tically significant differences in frequency of this variant
between cases and controls in large Scottish or Swedish
populations. Similar results were reported by Franke et al.,
[8] (German subjects) and Tremelling et al., [9] (East
Anglian subjects).
We are not certain of the functionality of the SNPs in the
present study. We note that the insertion-deletion poly-
morphism (ND(1)+32656) that has given such variable
Table 4: Allelic odds ratios and 95% confidence intervals for comparison of NOD1/CARD4 variants with IBD status in New Zealand IBD 
patients and Caucasians
Allelic odds ratios and 95% confidence 
intervals for comparison of NOD1 
rs2075818
Allelic odds ratios and 95% confidence 
intervals for comparison of NOD1 
rs2075822
Allelic odds ratios and 95% confidence 
intervals for comparison of NOD1 
rs2907748
CD UC CD UC CD UC
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Female 0.66 (0.46–0.96) 0.94 (0.65–1.36) 1.14 (0.79–1.64) 1.18 (0.81–1.71) 0.94 (0.66–1.34) 0.87 (0.60–1.25)
Male 0.66 (0.42–1.04) 1.02 (0.68–1.54) 1.03 (0.66–1.61) 1.33 (0.86–2.05) 0.71 (0.46–1.09) 0.76 (0.51–1.13)
Age at first 
diagnosis
0–16 years 0.62 (0.33–1.15) 0.94 (0.48–1.83) 0.75 (0.44–1.28) 1.11 (0.56–2.20) 1.11 (0.65–1.90) 1.20 (0.65–2.23)
17–40 years 0.67 (0.48–0.94) 0.91 (0.66–1.26) 1.03 (0.75–1.42) 1.17 (0.84–1.64) 0.88 (0.64–1.20) 0.83 (0.60–1.14)
>40 years 0.66 (0.46–0.95) 1.06 (0.77–1.45) 1.36 (0.94–1.96) 1.36 (0.97–1.91) 0.72 (0.51–1.02) 0.78 (0.57–1.07)
CD location
Ileal 0.82 (0.56–1.19) 1.15 (0.79–1.67) 0.71 (0.49–1.03)
Colonic 0.59 (0.41–0.85) 1.22 (0.86–1.72) 0.80 (0.57–1.11)
Ileocolonic 0.60 (0.38–0.94) 0.89 (0.60–1.33) 1.03 (0.69–1.53)
UC location
Proctitis 0.94 (0.67–1.32) 1.05 (0.74–1.49) 1.04 (0.75–1.44)
Left colon 1.14 (0.79–1.65) 1.43 (0.95–2.16) 0.85 (0.58–1.24)
Pancolitis 0.92 (0.65–1.31) 1.40 (0.96–2.03) 0.58 (0.40–0.84)
CD Behavior
Inflammatory 0.59 (0.42–0.82) 1.10 (0.80–1.51) 0.87 (0.64–1.18)
Stricturing 0.67 (0.45–0.99) 1.23 (0.84–1.81) 0.67 (0.46–0.98)
Penetrating 1.00 (0.60–1.66) 0.85 (0.52–1.40) 1.15 (0.71–1.87)
Ileal/Stricturing 0.71 (0.45–1.13) 1.44 (0.89–2.32) 0.48 (0.29–(0.79)
Colonic/
Inflammatory
0.61 (0.42–0.89) 1.20 (0.84–1.72) 0.82 (0.58–1.16)
Any relative with 
IBD
0.43 (0.25–0.73) 0.72 (0.44–1.17) 1.06 (0.68–1.66) 1.37 (0.84–2.24) 0.79 (0.51–1.22) 0.57 (0.35–0.93)
Bowel resection 0.75 (0.52–1.08) 0.91 (0.58–1.43) 1.10 (0.77–1.58) 0.88 (0.57–1.36) 0.72 (0.50–1.03) 1.28 (0.85–1.93)
Smoker at 
diagnosis
0.84 (0.56–1.26) 1.16 (0.71–1.90) 1.40 (0.92–2.14) 1.09 (0.65–1.83) 0.69 (0.46–1.03) 0.75 (0.45–1.26)
Ever used 
immunomodulator
s
0.70 (0.50–0.98) 0.90 (0.59–1.36) 1.18 (0.85–1.64) 1.10 (0.72–1.67) 0.81 (0.59–1.11) 0.94 (0.63–1.40)
Any EIMs 0.60 (0.37–0.97) 0.77 (0.48–1.24) 1.08 (0.69–1.68) 1.25 (0.77–2.02) 0.93 (0.61–1.42) 0.80 (0.51–1.27)BMC Research Notes 2009, 2:52 http://www.biomedcentral.com/1756-0500/2/52
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results in IBD population studies accounted for approxi-
mately 7% of the variation in IgE in two panels of families
(P < 0.0005 in each)[18]. That is, there is in vivo evidence
for functionality. According to our data the infection of
Caco2 cells with the adherent-invasive Escherichia coli
(AIEC) strain LF82 leads to the transcriptional activation
of Nod1. AIEC strains have been specifically associated
with CD ileal mucosa with a prevalence of 36.4% [19].
Taken together, these data may suggest that NOD1 plays a
variable role in different populations that could depend
upon environmental and dietary factors. The gene may be
especially important in Caucasian groups within New
Zealand
Methods
Participants and genotyping
Cases for this study were provided through the Canter-
bury Inflammatory Bowel Disease Project, and controls
randomly selected from a population-based cohort, both
of which are described more fully elsewhere [20,21]. Both
CD and UC were defined using standard diagnostic crite-
ria, and cases phenotyped according to the Montreal Clas-
sification systems [22].
This study had ethical approval from the Canterbury Eth-
ics Committee and the Southern Regional Health Author-
ity's Ethics Committee in Canterbury, New Zealand, and
all participants gave their written informed consent.
Genotyping was performed using the Sequenom MassAr-
ray® platform (Sequenom, San Diego, CA, USA) [23] using
a chip-based matrix-assisted laser desorption ionisation-
time-of-flight (MALDI-TOF) mass spectrometer [24], as
previously described [12,13]. Multiplex SNP assays were
designed using SpectroDesigner software and real-
SNP.com online tools (Sequenom, San Diego, CA, USA).
Primers, sequences and assay conditions are shown in
Table 6.
To estimate genotype accuracy, approximately 12% of the
samples were genotyped in duplicate or triplicate. We esti-
mated the error rate to be <1%.
Bacterial strain and culture conditions for functional 
assays
E. coli strain LF82, isolated from a chronic ileal lesion of a
French patient with CD, was a kind gift of A. Darfeuille-
Michaud, Université Clermont I, Pathogénie Bactérienne
Intestinale, Clermont-Ferrand, France. Bacteria were
grown routinely in Luria-Bertani (LB) broth or on LB agar
plates overnight at 37°C.
Cell culture and infection protocol
The human colorectal cancer cell line Caco-2 was
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). Cells were cultured in Dul-
becco's modified Eagle medium (DMEM) with L-
glutamine supplemented with 10% heat-inactivated fetal
calf serum (Moregate, Hamilton, New Zealand), 1 mM
sodium pyruvate and 1 mM non essential amino acids. All
reagents were supplied from Invitrogen, Auckland, New
Zealand. Cultures were maintained at 37°C in a humidi-
fied 5% CO2 atmosphere. Monolayers were seeded in 24-
well tissue culture plates (BD, Bioscience, Auckland, New
Zealand) with 2 × 105 cells/well and incubated for 14
days. During this time the cell medium was constantly
replenished.
For infection experiments, bacteria were grown overnight
in LB broth at 37°C. Before starting the infection the cell
monolayers were washed twice with phosphate-buffered
Table 5: Haplotype analysis of three-SNP NOD1 haplotype in IBD patients and Caucasians in a New Zealand population.
Haplotype Case subject frequency (%) Control subject frequency (%) p-value OR (95% CI) Global score statistics
CD Three SNPs NOD1gregion
(rs2075818, rs2075822, 
rs2907748)
CCA 20.6 22.2 0.53 0.90 (0.67–1.21) χ2 = 9.55,
CTG 55.8 46.9 0.004 1.44 (1.12–1.85) df = 3,
GTA 3.3 4.2 0.25 0.77 (0.41–1.45) p = 0.02
GTG 16.0 21.7 0.02 0.68 (0.50–0.92)
UC Three SNPs NOD1gregion
(rs2075818, rs2075822, 
rs2907748)
CCA 19.5 22.2 0.23 0.83 (0.62–1.11) χ2 = 2.30,
CTG 51.9 46.9 0.14 1.19 (0.93–1.52) df = 3,
GTA 3.8 4.2 0.79 0.89 (0.48–1.63) p = 0.51
GTG 21.5 21.7 0.95 0.97 (0.72–1.30)BMC Research Notes 2009, 2:52 http://www.biomedcentral.com/1756-0500/2/52
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saline (PBS, pH 7.2). Each monolayer was infected in 1 ml
of the cell culture medium without FCS at a multiplicity
of infection (MOI) of 10 bacteria per epithelial cell. After
a 6-h and 9-h incubation period at 37°C with 10% CO2,
infected monolayers were washed three times with PBS
and the cells were trypsinated with 10% Trypsin-EDTA
(Invitrogen, Auckland, New Zealand). To remove the
trypsin cells were centrifuged for 1 min at 1500 rpm and
the cell pellets were stored at -80°C.
RNA isolation and RT-PCR
Total RNA was extracted from non-infected and infected
Caco2 cells using the RNeasy Mini Kit (Qiagen, Hilden,
Germany) following manufacturer's protocols. The RNA
Table 6: Primer and probe sequences for custom made Sequenom SNP genotyping assay for NOD1
Primer SNP_ID Probe Sequences
Forward primer rs2075818 ACGTTGGATGCACTCACATCCGCAATACTC
rs2075822 ACGTTGGATGAAGGGGAGCAACAGGTGGGC
rs2907748 ACGTTGGATGAGGGTGGGCTCCTCTACAG
Reverse primer rs2075818 ACGTTGGATGGGCAGGCACACACAATCTCC
rs2075822 ACGTTGGATGAAGGGCCATGGTCATGAGTC
rs2907748 ACGTTGGATGACAGAAGGTCAATGGGACTC
Extend primer rs2075818 TAAGAATGACTACTTCTCGGC
rs2075822 GGGCATCGGGAATGGCA
rs2907748 GTGGGCTCCTCTACAGGTAGCT
Infection with E. coli LF82 alters m RNA levels for Nod1 and NF-κB Figure 1
Infection with E. coli LF82 alters m RNA levels for Nod1 and NF-κB. Total RNA was isolated and cDNA synthesized 
by reverse transcription. Nod1 and NF-κB mRNA levels were assayed by real-time quantitative PCR using specific primers for 
these genes. cDNA levels were normalized using primers for Actin. Quantitative real time PCR reactions were performed in 
triplicate, and means and standard error plotted.BMC Research Notes 2009, 2:52 http://www.biomedcentral.com/1756-0500/2/52
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was quantified spectrophotometrically and then stored at
-80°C. Reverse transcription of 1.5 μg of total RNA to
complementary DNA (cDNA) was carried out using the
SuperScript™III First-strand Synthesis – Super Mix Kit
(Invitrogen, Auckland, New Zealand) and oligo(dT)20
primers, according to the standard protocol. The primers
used for PCR had the following sequences: NF-κB, 5'-
ACAAATGGGCTACACCGAAG-3', 5'-GGACAACGCAGT-
GGAATTTT-3'; Nod1, 5'-AGCTGAAGATGAATTTGG G
AAA 3', 5'-GCCGAGAAGTAGTCATTCTTCAG-3' and Actin
5'-CATTGCCGACAGGATGCA-3', 5'-CCGATCCACACG-
GAGTACTTG-3'. These sets of primers yield to PCR prod-
ucts that were 198 bp (Nod1), 341 bp (NF-κB) and 102
bp (Actin) long, respectively. Results are expressed as the
relative mRNA accumulation corrected using Actin mRNA
as an internal standard.
Statistical analysis
The allelic trend test [25] and Fisher's exact genotypic test
were used to compare case and control allele frequencies.
An exact test was used to test for departures from Hardy-
Weinberg equilibrium (HWE) in the case and the control
samples [26]. Allelic odds ratios were calculated and con-
fidence intervals for the allelic odds ratio were also calcu-
lated under the assumption of HWE in the cases and the
control groups. Logistic regression analysis was used for
subgroup analysis. Other analyses were carried out using
R [27], SHEsis [28] (available from http://analysis.bio-
x.cn/myAnalysis.php), and SAS (V9.1 SAS Institute., Cary,
NC, USA).
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